Medical and Pharmaceutical Psilocybin treats depression as well as common antidepressant: study The first head-to-head clinical trial pushes the psychedelic compound closer to becoming a licensed medicine Jared GnamApril 15, 2021
Canada Schedule I tea at the Coca Leaf Café Vancouver activist Dana Larsen is pushing the drug-reform conversation past cannabis by opening the doors of his entheogenic coffee shop Natalia Buendia CalvilloApril 7, 2021
Medical and Pharmaceutical LSD could be used to treat people with autism, study suggests Early evidence shows LSD promotes social behaviour in rodents, but pharmaceutical research is still a ways off Natalia Buendia CalvilloMarch 1, 2021
Medical and Pharmaceutical Nature amplifies therapeutic effects of psychedelics: study A recent review suggests natural settings and activities can complement all stages of psychedelic-assisted therapy Natalia Buendia CalvilloFebruary 23, 2021
Analysis Field Trip white paper makes strong health and business case for ketamine therapy With solid efficacy and low cost, the popular club drug could help curb the personal toll and multi-billion dollar cost of North America's battle... Natalia Buendia CalvilloFebruary 9, 2021
Canada Proposed amendment could greatly expand access to psychedelic therapy in Canada Proposed by Health Canada, the change would allow patients to access restricted substances like MDMA through the Special Access Program Natalia Buendia CalvilloJanuary 28, 2021
Psychedelics 2020’s top 5 advancements in psychedelics With major research, legal reform, and more than 20 firms going public, it was major year for the re-emerging field Jared GnamDecember 30, 2020
Analysis What happened to Canada’s ibogaine clinics? Following a surge of interest, ibogaine therapy in the country disappeared. But recent signs show regulators are warming to the promising plant Suzannah WeissDecember 23, 2020
Health and Safety What Measure 109 means for the future of psychedelic therapy After a successful ballot measure, a broad set of onlookers focuses on Oregon to gauge the social and economic impacts of licensed psilocybin therapy Amna ShamimDecember 15, 2020
Investment Ideas MagicMed aims to mainstream psychedelic therapy with world’s largest ‘Psybrary’ Through its university partnership, the firm wants to attract big pharma backers by making 100,000s of novel psychedelic derivatives for new precision medicine Jared GnamDecember 1, 2020